Search results for "ASTHMA"

showing 10 items of 860 documents

Depression is associated with poor control of symptoms in asthma and rhinitis: A population-based study

2019

Abstract Background Although many studies have highlighted the link between asthma/rhinitis and depression, it is still unclear which characteristics of these diseases are associated with the risk of depression. We aimed to explore the relationship between depression and asthma or rhinitis in a representative sample of the Italian general population. Methods The data were collected in GEIRD, an Italian multicenter, population-based, multicase-control study. 2227 participants (age 21–86 years, female 50%) underwent standardized interviews, skin prick and lung function tests, and were divided into cases of current asthma (n = 528), rhinitis without asthma (n = 972), and controls (n = 727). Tw…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyActivities of daily livingPopulationSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary function testingAtopyYoung Adult03 medical and health sciences0302 clinical medicineAsthma controlInternal medicinemedicineHumans030212 general & internal medicineMedical prescriptioneducationAgedRhinitisAsthmaAged 80 and overeducation.field_of_studyAtopyDepressionbusiness.industryAnhedoniaGeneral populationMiddle Agedmedicine.diseaseAsthmaPatient Health QuestionnaireItaly030228 respiratory systemAsthma control; Atopy; Depression; General population; Rhinitis controlRhinitis controlFemalemedicine.symptombusinessRespiratory Medicine
researchProduct

The Revised Asthma Problem Behavior Checklist: Adaptation for Use in Spanish Asthmatic Patients

1997

Behavioral problems associated with asthma management were examined in a group of 100 adult Spanish outpatients with asthma (57 women, 43 men; 17-69 years of age). All of them completed a Spanish version of the Revised Asthma Problem Behavior Checklist (RAPBC). Data about duration, severity, and self-management of asthma (self-efficacy expectancies and health care utilization), as well as dyspnea and FEV1, were also recorded. The highest-reliability Cronbach alpha indices were for the criteria related to emotions and behaviors that could precipitate asthma attacks. Concurrent criterion validity was examined first by Pearson correlations between the RAPBC scores and clinical data about asthm…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentHealth BehaviorCronbach's alphaQuality of lifeSurveys and QuestionnairesHealth careCriterion validityHumansImmunology and AllergyAsthmatic patientMedicineAgedLanguageAsthmaAnalysis of VarianceBehaviorbusiness.industryReproducibility of ResultsMiddle Agedmedicine.diseaseAsthmaChecklistrespiratory tract diseasesSelf CarePediatrics Perinatology and Child HealthPhysical therapyFemaleAnalysis of variancebusinessClinical psychologyJournal of Asthma
researchProduct

Gender Differences in Health‐Related Quality of Life Among Patients with Asthma

2004

This study has a twofold objective: 1) to explore to what extent suffering from asthma affects the HRQL of men and women differently at several stages of disease severity and 2) to analyze whether the informed poorer HRQL of asthmatic women is related to their higher scores on instruments measuring emotionally disordered symptoms. One hundred fifty-one outpatient asthmatics (84 women and 67 men) completed the Spanish versions of the Asthma Quality of Life questionnaire (AQL), as well as anxiety and depression inventories. A full history, physical examination, and pulmonary function test were performed on all subjects. Patients were classified into one of four asthma severity categories foll…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentPhysical examinationmacromolecular substancesSeverity of Illness IndexPulmonary function testingSex FactorsQuality of lifeSeverity of illnessmedicineHumansImmunology and AllergyDepression (differential diagnoses)AsthmaDepressive Disordermedicine.diagnostic_testbusiness.industryRespiratory diseaseMiddle Agedmedicine.diseaseAnxiety DisordersAsthmarespiratory tract diseasesDyspneaPediatrics Perinatology and Child HealthQuality of LifePhysical therapyAnxietyFemalemedicine.symptombusinessClinical psychologyJournal of Asthma
researchProduct

Reslizumab as add-on therapy in patients with refractory asthma

2020

### Key messages #### What is the key question? #### What is the bottom line? #### Why read on? Asthma is a common disease, affecting an estimated 334 million people worldwide, with considerable impact on quality of life and high associated costs.1–3 Asthma severity is assessed retrospectively from the level of treatment required to control symptoms and exacerbations. Approximately 5%–10% of patients with asthma are believed to suffer from severe disease.4 Patients with severe asthma typically require ongoing maintenance therapy with high-dose inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA).2 Furthermore, systemic corticosteroids (SCS) are often required for potentially life-th…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentmedicine.drug_classCost-Benefit Analysislcsh:MedicineInflammationAntibodies Monoclonal HumanizedYoung Adult03 medical and health sciences0302 clinical medicineReslizumabQuality of lifeMaintenance therapyAdrenal Cortex HormonesInternal medicinemedicineHumans1506Anti-Asthmatic Agents030212 general & internal medicineChildAdrenergic beta-2 Receptor AgonistsPulmonary EosinophiliaAgedAsthmalcsh:RC705-779business.industrylcsh:Rlcsh:Diseases of the respiratory systemMiddle AgedEosinophilmedicine.diseaseAsthmarespiratory tract diseasesTreatment Outcomemedicine.anatomical_structure030228 respiratory systempulmonary eosinophiliaRegression AnalysisCorticosteroidFemalemedicine.symptombusinessmedicine.drugBMJ Open Respiratory Research
researchProduct

A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in pa…

2019

Abstract Introduction Mometasone furoate (MF) is the inhaled corticosteroid (ICS) component in the long-acting β2-agonist (LABA)/ICS fixed-dose combination of indacaterol/MF, delivered via Breezhaler®, in development for asthma. MF at low (80 μg) and high (320 μg) doses delivered via Breezhaler® is expected to be comparable to MF at low (200 μg) and high (800 μg) doses respectively, delivered via Twisthaler®. Methods This was a randomized, double-blind, double-dummy, four-week, parallel-group study of 739 adolescents and adults with persistent asthma. Eligible patients were receiving ICS treatment up to the maximum dose per day on a stable regimen for at least four weeks before screening. T…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentmedicine.drug_classUrologyMometasone furoateRandom AllocationYoung Adult03 medical and health sciences0302 clinical medicineDouble-Blind MethodAdrenal Cortex HormonesAdministration InhalationmedicineClinical endpointHumansPharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicineAdverse effectLungAgedAsthmaAged 80 and overbusiness.industryBiochemistry (medical)Middle Agedmedicine.diseaseAsthmaDrug CombinationsRegimenTreatment Outcome030228 respiratory systemAsthma Control QuestionnaireCorticosteroidIndacaterolFemalebusinessMometasone Furoatemedicine.drugPulmonary Pharmacology & Therapeutics
researchProduct

Spontaneous gastroesophageal reflux and airway patency during the night in adult asthmatics

2000

Controversies still exist on the role of nighttime gastroesophageal reflux (GER) in precipitating nocturnal asthma. We tested the relationship between GER and nocturnal bronchoconstriction by continuously and simultaneously monitoring both respiratory resistances and esophageal pH in seven asthmatics with moderate to severe GER disease. Twenty-nine GER episodes were found during the study night lasting more than 5 min (LGER) and 72 not longer than 5 min (SGER). Both long (LGER) and short (SGER) gastroesophageal refluxes were able to maintain significantly higher lower respiratory resistances (RLR) at the resolution of each GER episode (RLR(e)) with respect to baseline values. RLR, expressed…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAirway patencyPrognosiBronchoconstrictionPolysomnographySettore MED/10 - Malattie Dell'Apparato RespiratorioNocturnalEsophaguCritical Care and Intensive Care MedicineSeverity of Illness IndexGastroenterologyEsophagusInternal medicinemedicineHumansRespiratory systemAsthmaEsophageal diseasebusiness.industryAirway ResistancefungiRespiratory diseaseRefluxHydrogen-Ion ConcentrationMiddle AgedPrognosismedicine.diseaseAsthmaCircadian RhythmSurgeryGastroesophageal RefluxFemaleBronchoconstrictionmedicine.symptombusinessHuman
researchProduct

Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany

2009

Omalizumab is a humanized monoclonal anti-immunoglobulin E (IgE) antibody indicated in Europe for the treatment of uncontrolled severe persistent allergic (IgE-mediated) asthma despite optimal therapy with inhaled corticosteroids and long-acting beta(2) agonists. Between 2005 and 2007 280 patients (58% female, mean age 44+/-16 yrs., 46% on oral corticosteroids, median serum IgE level 235IU/ml) who met the EU criteria for add-on therapy with anti-IgE were treated prospectively with omalizumab by 134 physicians as part of a post-marketing surveillance trial and were followed-up for 6 months. The median follow-up time was 195 days, the patients were treated with a median dose of 450mg omalizum…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAllergyAdolescentAllergyOmalizumabOmalizumabAntibodies Monoclonal HumanizedImmunoglobulin ESeverity of Illness IndexYoung AdultQuality of lifeAdrenal Cortex HormonesForced Expiratory VolumeGermanyInternal medicineSeverity of illnessHypersensitivityHumansMedicineAnti-Asthmatic AgentsProspective StudiesChildProspective cohort studyAdverse effectAsthmaDose-Response Relationship Drugbiologybusiness.industryAntibodies MonoclonalMiddle Agedmedicine.diseaseAsthmaAntibodies Anti-IdiotypicSurgeryTreatment Outcomebiology.proteinFemaleIgETherapybusinessmedicine.drugRespiratory Medicine
researchProduct

Differences in sensitivity, maximal response and position of the concentration-response curve to methacholine between asthmatics, patients with aller…

1998

The aim of this study was to detect differences in maximal response and position of the concentration-response curves to methacholine between asthmatics and subjects with allergic rhinitis. A total of 228 adults (107 mild asthmatics, 96 allergic rhinitics and 25 healthy control subjects) were challenged with methacholine. The test was interrupted when FEV1 dropped by more than 40% or when the highest concentration of methacholine (200 mg ml-1) had been administered. Concentration-response curves were characterized by their PC20 (concentration of methacholine that produced 20% fall in FEV1 = airway sensitivity), and if possible, by their EC50 (concentration of methacholine that produced 50% …

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAllergyGastroenterologySensitivity and SpecificityBronchoconstrictor AgentsInternal medicinemedicineHumansLung volumesMethacholine ChlorideAsthmaEC50RhinitisSkin TestsAnalysis of VarianceConcentration ResponseDose-Response Relationship Drugbusiness.industrymedicine.diseaseAsthmaRespiratory Function TestsDose–response relationshipAnesthesiaMethacholineFemaleAnalysis of varianceBronchial Hyperreactivitybusinessmedicine.drugRespiratory Medicine
researchProduct

Cigarette Smoking, But Not Sensitization toAlternaria, Is Associated with Severe Asthma in Urban Patients

2001

Hereditary susceptibility and allergen exposure have been identified as general risk factors for asthma. However, risk factors for severe asthma still remain to be identified. To further assess and quantify risk factors associated with severe asthma in adult patients apart from clinical exacerbations, 306 randomly selected subjects (mean age 40+/-17 years, 46% males) presenting to an inner city pulmonary practice between 1995 and 1996 were retrospectively investigated. Of these, 117 patients were atopic, 112 had current asthma, and 22 asthmatics had severe asthma. Risk factors associated with atopy were family history of atopy and any domestic pet ownership (OR: 3.1, 95% CI: 1.64-6.1). Asth…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAllergyUrban Populationmedicine.disease_causeSeverity of Illness IndexAtopyAllergenRisk FactorsForced Expiratory VolumeGermanyInternal medicineImmunopathologyHypersensitivitymedicineHumansImmunology and AllergyFamily historyRisk factorRetrospective StudiesAsthmabusiness.industrySmokingRespiratory diseaseUrban HealthAlternariamedicine.diseaseAsthmarespiratory tract diseasesMultivariate AnalysisPediatrics Perinatology and Child HealthImmunologyFemalebusinessJournal of Asthma
researchProduct

Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy

2015

Few data are available on the proportion of asthmatics achieving a good asthma control (according GINA guidelines) and on the level of airway inflammation during omalizumab treatment. The aim of this cross-sectional national observational study was to assess the level of control (according to GINA guidelines) achieved in a group of asthmatics on omalizumab treatment, and to characterize the factors that influence the lack of control. We studied 306 asthmatics under omalizumab treatment for a median of 32 months (range 4-120). The level of control according to GINA was good in 25.2%, partial in 47.1% and poor in 24.5% of patients (data were missing for the remaining 3.2%). Comparison between…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyExacerbationCross-sectional studyOmalizumabOmalizumabComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioExhaled nitric oxide; Exacerbations; Comorbidities; Asthma; Omalizumab; ControlSeverity of Illness IndexComorbiditiesExacerbationsExhaled nitric oxideInternal medicineSeverity of illnessControlMedicineAnti-Asthmatic AgentHumansPharmacology (medical)Anti-Asthmatic AgentsInflammation MediatorAsthmaRespiratory Function TestAgedCross-Sectional Studiebusiness.industryBiochemistry (medical)ExacerbationMiddle Agedmedicine.diseaseComorbidityAsthmaRespiratory Function TestsCross-Sectional StudiesItalyExhaled nitric oxidePhysical therapyObservational studyAsthma; Comorbidities; Control; Exacerbations; Exhaled nitric oxide; Omalizumab; Adult; Aged; Anti-Asthmatic Agents; Asthma; Comorbidity; Cross-Sectional Studies; Female; Humans; Inflammation Mediators; Italy; Male; Middle Aged; Omalizumab; Respiratory Function Tests; Severity of Illness Index; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)FemaleComorbiditieInflammation Mediatorsbusinessmedicine.drugHuman
researchProduct